PDRN for Post-Surgical Scarring: Accelerating Wound Resolution and Improving Scar Quality

How PDRN Targets Post-Surgical Scarring

PDRN improves post-surgical scar quality by optimizing each phase of the wound healing process. During the inflammatory phase (days 1-7), A2A receptor activation on macrophages and neutrophils suppresses excessive TNF-alpha, IL-6, and IL-8 release, preventing the prolonged inflammatory state that drives fibrotic scarring while preserving the constructive inflammation needed for wound debridement. During the proliferative phase (days 7-21), PDRN stimulates fibroblast proliferation and migration into the wound bed, accelerates re-epithelialization by keratinocytes, upregulates organized collagen and glycosaminoglycan synthesis, and promotes angiogenesis through VEGF modulation to establish blood supply in the healing tissue. During the remodeling phase (weeks 3 to months), PDRN's continued anti-inflammatory signaling creates an environment that favors organized type I collagen replacement of initial type III collagen, resulting in stronger, flatter, softer scars with better color match to surrounding skin. The nucleotide salvage pathway ensures all rapidly dividing wound cells have adequate substrates for DNA replication, preventing cellular stalling that can delay wound closure and worsen scarring.

The key determinant of scar quality is the balance between collagen production and collagen organization during the remodeling phase. In normal wound healing, type III collagen initially deposited during the proliferative phase is gradually replaced by stronger type I collagen in an organized, parallel pattern that mimics the surrounding skin architecture. When this process goes awry — typically due to prolonged inflammation, excessive mechanical tension, or dysregulated growth factor signaling — collagen is deposited in a disorganized, tangled pattern that creates raised, firm, and aesthetically unsatisfactory scars.

PDRN (polydeoxyribonucleotide) is uniquely positioned to improve post-surgical scar outcomes because it was originally developed for wound healing and its mechanisms directly target the key processes that determine scar quality. PDRN's adenosine A2A receptor activation provides potent anti-inflammatory effects that help transition the wound from the inflammatory phase to the proliferative phase more quickly and cleanly — this faster resolution of inflammation is strongly correlated with better scar outcomes because prolonged inflammation drives the fibrotic, disorganized collagen deposition that characterizes hypertrophic scars and keloids.

Simultaneously, PDRN stimulates fibroblast proliferation and collagen synthesis through A2A signaling, ensuring robust tissue repair while the anti-inflammatory context promotes organized rather than fibrotic collagen deposition. The nucleotide salvage pathway provides DNA building blocks to the rapidly dividing cells at the wound margin — fibroblasts, keratinocytes, and endothelial cells — accelerating wound closure and reducing the window of vulnerability to infection and mechanical disruption. PDRN also promotes angiogenesis through balanced VEGF modulation, ensuring adequate blood supply to the healing tissue for oxygen delivery and waste removal, which are critical for organized scar maturation.

In Korean plastic surgery and dermatology, PDRN injections around surgical incision sites have become a standard adjunct treatment for improving scar outcomes. Clinical experience shows that PDRN-treated surgical wounds demonstrate faster wound closure, reduced post-surgical inflammation, improved collagen organization, flatter and softer final scars, and better color matching with surrounding skin. For patients concerned about visible scarring from upcoming or recent surgery, PDRN offers a scientifically grounded approach to optimizing wound healing at every phase.